New drug combo aims to fight bladder cancer when standard treatment fails

NCT ID NCT06388720

Recruiting now Disease control Sponsor: National Cancer Center, Korea Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a two-drug combination (mitomycin-C and gemcitabine) given directly into the bladder for people with high-risk bladder cancer that did not respond to BCG therapy. The study will enroll 82 participants to see if this sequential treatment can prevent cancer from coming back or getting worse. Researchers will also monitor safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mitomycin-C and gemcitabine
What this could lead to: If successful, this could offer a new treatment option for people with high-risk bladder cancer that hasn't responded to standard therapy, potentially delaying recurrence or progression.
What could go wrong: This is a small, early-phase (phase 2) trial with only 82 participants, so results may not apply to everyone. The treatment may not work better than existing options, and side effects from the bladder instillations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma superficial urinary bladder carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER

Contacts and locations

Locations

National Cancer Center
RECRUITING

Goyang-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.